Avant Diagnostics Highlights Published Clinical Utility Data for Theralink® mTOR Pathway...
Stockhouse,
/PRNewswire/ -- Two thirds of all breast cancer (BC) tumors are estrogen receptor positive (ER)+ ER+ BC patients have mixed…
Avant Diagnostics Highlights Published Clinical Utility Data for Theralink® mTOR Pathway Activation Data Predicting Tamoxifen® and Other Endocrine Treatment Response in Estrogen Receptor Positive (ER+) Breast Cancer
KUSI News,
SOURCE Avant Diagnostics, Inc. GAITHERSBURG, Maryland Two thirds of all breast cancer (BC) tumors are estrogen receptor…
Avant Diagnostics Highlights Published Clinical Utility Data for Theralink® mTOR Pathway Activation Data Predicting Tamoxifen® and Other Endocrine Treatment Response in Estrogen Receptor Positive (ER+) Breast Cancer
WLOX,
SOURCE Avant Diagnostics, Inc. GAITHERSBURG, Maryland Two thirds of all breast cancer (BC) tumors are estrogen receptor…
Avant Diagnostics Highlights Published Clinical Utility Data for Theralink® mTOR Pathway Activation Data Predicting Tamoxifen® and Other Endocrine Treatment Response in Estrogen Receptor Positive (ER+) Breast Cancer
NewsWest9,
SOURCE Avant Diagnostics, Inc. GAITHERSBURG, Maryland Two thirds of all breast cancer (BC) tumors are estrogen receptor…